Elvitegravir NEW
| Price | $47 | $79 | $155 |
| Package | 5mg | 10mg | 25mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2024-11-05 |
Product Details
| Product Name: Elvitegravir | CAS No.: 697761-98-1 |
| Purity: 99.73% | Supply Ability: 10g |
| Release date: 2024/11/05 |
Product Introduction
Bioactivity
| 名稱 | Elvitegravir |
| 描述 | Elvitegravir (JTK-303) is a Human Immunodeficiency Virus Integrase Strand Transfer Inhibitor. The mechanism of action of elvitegravir is as an HIV Integrase Inhibitor, and Cytochrome P450 2C9 Inducer. |
| 細胞實驗 | Elvitegravir (EVG) is prepared in DMSO and stored, and then diluted with appropriate medium before use[1]. MT-2 cells (2×105 cells) are infected with HIV-1 IIIB and then cultured in the presence of 0.5 nM or 0.1 nM Elvitegravir. Cultures are incubated at 37°C until an extensive cytopathic effect (CPE) is observed, and the culture supernatant is then harvested for further passage in fresh MT-2 cells. The concentration of Elvitegravir is increased when a significant CPE is observed. At the indicated passages, proviral DNA is extracted from infected MT-2 cells and then subjected to PCR, followed by direct population-based sequencing. Susceptibility to Elvitegravir at the indicated passages is determined using the MAGI assay or p24 production[1]. |
| 體內(nèi)活性 | Elvitegravir inhibits the replication of MLV infection with an IC50 of 5.8 nM and also suppresses the primate retrovirus SIV with an IC50 of 0.5 nM, demonstrating its activity against multiple retroviruses due to IN inhibitor properties. It inhibits integrase activity with an IC50 of 6 nM and affects PBMC and PA with IC50 values of 0.89 nM and 20 nM, respectively. Additionally, Elvitegravir blocks the synthesis of chain transfer products with an IC50 of 54 nM by inhibiting integration via IN-regulated chain transfer. EVG exhibits antiviral activity without serum, with IC50 values ranging from 0.3 to 0.9 nM, targeting peripheral blood mononuclear cells and effectively inhibiting HIV-1 and HIV-2. |
| 存儲條件 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| 溶解度 | DMSO : 82 mg/mL (183.1 mM) Ethanol : 33 mg/mL (73.7 mM) H2O : < 1 mg/mL (insoluble or slightly soluble) |
| 關(guān)鍵字 | inhibit | HIV-1IIIB | HIV-2EHO | HIV | GS 9137 | JTK 303 | HIV Integrase | cDNA | D-06677 | Inhibitor | GS9137 | HIV-2ROD | JTK303 | Elvitegravir | D 06677 | Human immunodeficiency virus |
| 相關(guān)產(chǎn)品 | Stavudine | 5-Fluorouracil | Emtricitabine | Kaempferol | Dolutegravir intermediate-1 | Dextran sulfate sodium salt (MW 4500-5500) | Lamivudine | Chloroquine phosphate | Decanedioic acid | Tenofovir |
| 相關(guān)庫 | 經(jīng)典已知活性庫 | ReFRAME 相關(guān)化合物庫 | 肝臟毒性化合物庫 | EMA 上市藥物庫 | 藥物功能重定位化合物庫 | 抗病毒庫 | 抑制劑庫 | FDA 上市藥物庫 | 臨床期小分子藥物庫 | 已知活性化合物庫 |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $15.00/1KG |
Zhuozhou Wenxi import and Export Co., Ltd
|
2021-07-10 | ||
| $198.00/50mg |
VIP6Y
|
BOC Sciences
|
2020-05-15 | |
| $1.00/25Kg/Drum |
HubeiwidelychemicaltechnologyCo.,Ltd
|
2019-10-29 | ||
| $2.00/1kg |
VIP7Y
|
Career Henan Chemical Co
|
2018-12-24 | |
| $15.00/1KG |
Zhuozhou Wenxi import and Export Co., Ltd
|
2021-07-09 |
United States- Since: 2011-01-07
- Address: 36?Washington?Street, Wellesley?Hills
INQUIRY